This list is an analysis based on recent market events. It's not an investment recommendation.
About
ViGenCell Inc. provides immune cell therapy in South Korea. It develops ViTier, an antigen-specific killer T cell therapy, such as VT-EBV-N for NK/T Lymphoma indications and VT-Tri(1)-A for AML indications; ViMedier, a cord blood-derived myeloid suppressor cell therapy, including VM-GD for GvHD indications and VM-AD for atopic dermatitis indications; and ViRanger, an off-the-shelf allogenic universal T cell gene therapy comprising VR-CAR and VR-GDT for hepatoma and leukemia indications. The company was founded in 2013 and is based in Seoul, South Korea.
The current price of 308080.KQ is ₩4,470 KRW — it has decreased by -4.69% in the past 24 hours. Watch ViGenCell stock price performance more closely on the chart.
What is ViGenCell stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on KOSDAQ exchange ViGenCell stocks are traded under the ticker 308080.KQ.
Is ViGenCell stock price growing?▼
308080.KQ stock has fallen by -11.83% compared to the previous week, the month change is a -23.06% fall, over the last year ViGenCell has showed a +34.03% increase.
What is ViGenCell market cap?▼
Today ViGenCell has the market capitalization of 86.11B
What is ViGenCell revenue for the last year?▼
ViGenCell revenue for the last year amounts to 278.95M KRW.
What is ViGenCell net income for the last year?▼
308080.KQ net income for the last year is -14.06B KRW.
How many employees does ViGenCell have?▼
As of November 3, 2026, the company has 64 employees.
In which sector is ViGenCell located?▼
ViGenCell operates in the Energy sector.
When did ViGenCell complete a stock split?▼
The last stock split for ViGenCell was on June 8, 2022 with a ratio of 1:1.